With the development of molecular biology, molecular targeted therapy based on the molecular mechanism of EGFR-TKI and targeted diverse resistance mechanisms has become the new direction fir advanced NSCLC precision medicine. Here, EGFR is linked to non-small cell lung carcinoma.